Cardioprotective effect of pretreatment with β-glucan in coronary artery bypass grafting

Abstract

Background. β-glucan pretreatment has been shown to attenuate inflammatory response and to protect against ischemia-reperfusion injury in animal studies. The aims of the present study were to examine the safety of pretreatment with β-1,3/1,6-glucan in patients scheduled for coronary artery bypass grafting (CABG), and to investigate whether β-1,3/1,6-glucan pretreatment could suppress inflammatory response and protect against ischemia-reperfusion injury following CABG. Methods. Twenty one patients scheduled for CABG were assigned to oral β-1,3/1,6-glucan 700-mg (Group 1) or 1-400-mg (Group 2) five consecutive days before surgery and were compared with a control group (Group 3). Blood samples were drawn preoperatively and on the first, third and fifth postoperative day for analysis of acute-phase reactants, hematology, cytokines and myocardial enzymes. Results. The study drug was well tolerated. Creatine kinase isoenzyme MB was significantly lower in Group 2 compared with controls on the first postoperative day (p=0.028). Mean change in cardiac troponin T was lower in Group 2 compared with controls (p=0.028). Conclusions. β-1,3/1,6-glucan pretreatment is safe in patients undergoing CABG and may protect against ischemia reperfusion injury following CABG.